Related Experiment Video

Updated: Nov 8, 2025

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

2.1K

SGLT-2 inhibition in IgA nephropathy: the new standard of care?

Jonathan Barratt1, Jürgen Floege2

  • 1Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.

Kidney International
|April 20, 2021
PubMed

Insights

Dapagliflozin shows promise in slowing IgA nephropathy progression, offering a potential new treatment option. This study suggests it may be a safe and effective addition to existing therapies for IgA nephropathy patients.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • IgA nephropathy (IgAN) is a common cause of chronic kidney disease (CKD).
  • Current treatments for IgAN have limited efficacy and potential toxicity.
  • Many IgAN patients progress to end-stage kidney disease despite supportive care.

Purpose of the Study:

  • To evaluate the safety and efficacy of dapagliflozin in patients with IgA nephropathy.
  • To assess dapagliflozin as an adjunct to standard care for IgAN.

Main Methods:

  • A subanalysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease Trial.
  • Inclusion of 270 patients diagnosed with IgA nephropathy.
  • Evaluation of dapagliflozin's effects on IgAN progression and safety.

Main Results:

  • Early evidence suggests dapagliflozin is safe for IgAN patients.
  • Dapagliflozin may be effective in managing IgA nephropathy.
  • The drug shows potential as part of the standard of care.

Conclusions:

  • Dapagliflozin offers a potential new therapeutic avenue for IgA nephropathy.
  • Further research is warranted to confirm dapagliflozin's long-term benefits in IgAN.
  • This study provides a foundation for dapagliflozin use in IgAN management.

More Related Videos

Highly Sensitive Measurement of Glomerular Permeability in Mice with Fluorescein Isothiocyanate-polysucrose 7009:16

Highly Sensitive Measurement of Glomerular Permeability in Mice with Fluorescein Isothiocyanate-polysucrose 70

Published on: August 9, 2019

7.1K
Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

2.0K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
326
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
55
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
796
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
530
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
368
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
173